NEW YORK--(BUSINESS WIRE)--BlinkRx, the world’s most advanced patient access platform for branded medications, is excited to announce a new partnership with ARS Pharmaceuticals to offer neffy®, the needle-free epinephrine nasal spray, now available on its platform. neffy is the first and only needle-free treatment for severe allergic reactions, including life-threatening anaphylaxis for children and adults who weigh 30kgs (66lbs.) or more.

纽约--（商业新闻短讯）--全球最先进的品牌药物患者访问平台BlinkRx很高兴宣布与ARS Pharmaceuticals建立新的合作伙伴关系，提供neffy®，无针肾上腺素鼻喷雾剂，现已在其平台上提供。neffy是第一个也是唯一一个治疗严重过敏反应的无针疗法，包括对体重30公斤（66磅）或以上的儿童和成人的危及生命的过敏反应。

Now, prescribed patients can conveniently access neffy through the BlinkRx platform, a service that provides patients transparent prices, free home delivery, and personalized, concierge-level support..

现在，处方患者可以通过BlinkRx平台方便地访问neffy，该服务为患者提供透明的价格，免费送货上门以及个性化的礼宾级支持。。

neffy is the first innovation in epinephrine delivery in over 35 years. There are approximately 40 million people in the U.S. who experience Type I allergic reactions due to food, venom or insect stings. Of those, only 3.3 million patients each year fill an epinephrine needle-injector prescription, in which only about half consistently carry one device.

neffy是35年来肾上腺素输送方面的首次创新。美国大约有4000万人因食物、毒液或昆虫叮咬而经历I型过敏反应。其中，每年只有330万患者服用肾上腺素针剂处方，其中只有大约一半的患者始终携带一种设备。

For patients and caregivers who carry a needle-injector, more than half either delay or do not administer in an emergency, and each year, it is estimated that Type 1 allergic reactions result in 500,000 emergency room visits. neffy is designed to address this issue by providing a needle-free, easy-to-use option that can be quickly administered in emergency situations, helping to ensure that more patients receive the necessary treatment they need..

对于携带针头注射器的患者和护理人员，超过一半的人在紧急情况下延迟或不给药，据估计，每年1型过敏反应导致50万次急诊就诊。。。

“We’re thrilled to make neffy available through BlinkRx so people with severe allergic reactions can have a needle-free option for treating symptoms of anaphylaxis,” said ​​Richard Lowenthal, CEO and President of ARS Pharmaceuticals. “Through neffyConnect, and in partnership with BlinkRx, eligible commercially insured patients will pay $25 for two single-use neffy devices through a co-pay savings program.

ARS Pharmaceuticals首席执行官兼总裁理查德·洛文塔尔（RichardLowenthal）表示：“我们很高兴能通过BlinkRx为neffy提供服务，这样严重过敏反应患者就可以无针治疗过敏反应症状了。”。“通过neffyConnect，并与BlinkRx合作，符合条件的商业保险患者将通过共同付费储蓄计划为两台一次性使用的neffy设备支付25美元。

For patients without insurance coverage, or for those whose insurance plans do not yet cover neffy, ARS Pharmaceuticals is offering a cash price of $199 through BlinkRx. By partnering, we’re making it easier for patients and caregivers to access the treatments they need, when they need it.”.

对于没有保险的患者，或者那些保险计划尚未涵盖内菲的患者，ARS制药公司通过BlinkRx提供199美元的现金价格。通过合作，我们使患者和护理人员在需要时更容易获得所需的治疗。”。

Geoffrey Chaiken, CEO of Blink Health, added, “At BlinkRx, our mission is to ensure that essential medications are easily within reach for everyone. Making neffy available on our platform enhances the accessibility of epinephrine for patients in need, especially for underserved communities.”

Blink Health首席执行官杰弗里·柴肯（GeoffreyChaiken）补充道：“在BlinkRx，我们的使命是确保每个人都能轻松获得基本药物。在我们的平台上提供neffy可以增强需要肾上腺素的患者的可及性，特别是对于服务不足的社区。”

About BlinkRx

关于BlinkRx

BlinkRx is revolutionizing the pharmacy experience, using cutting-edge technology to dramatically improve patient access for branded medications. Health care providers benefit from dedicated access teams and streamlined prior authorization support for patients. Patients enjoy affordable, transparent pricing, co-pay assistance, free home delivery, and personalized support.

BlinkRx正在彻底改变药房体验，使用尖端技术极大地改善患者获得品牌药物的机会。医疗保健提供者受益于专门的访问团队，并简化了对患者的事先授权支持。患者享有负担得起的、透明的定价、共同支付的帮助、免费送货上门和个性化支持。

Learn more at www.blinkrx.com..

Learn more at www.blinkrx.com..

Stay Connected:

保持联系：

www.blinkrx.com

www.blinkrx.com

Blink Health LinkedIn

眨眼健康LinkedIn